FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
The company buys Belgium’s EsoBiotec for $425m.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.